For research use only. Not for therapeutic Use.
Desmopressin(CAT: I002180) is a medication that is used to treat a variety of conditions, including diabetes insipidus, bedwetting, and certain bleeding disorders. Desmopressin is a synthetic analog of vasopressin, a hormone that regulates water balance in the body. It works by increasing the reabsorption of water in the kidneys, which can help reduce urine output in people with diabetes insipidus and bedwetting. In people with bleeding disorders, desmopressin can increase levels of von Willebrand factor, a protein that helps with blood clotting.
| Catalog Number | I002180 |
| CAS Number | 16679-58-6 |
| Synonyms | 1-(7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)-N-(1-((2-amino-2-oxoethyl)amino)-5-((diaminomethylene)amino)-1-oxopentan-2-yl)pyrrolidine |
| Molecular Formula | C46H64N14O12S2 |
| Purity | ≥95% |
| Target | Vasopressin Receptor |
| Solubility | water:4 mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | (2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide |
| InChI | InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1 |
| InChIKey | NFLWUMRGJYTJIN-PNIOQBSNSA-N |
| SMILES | C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N |
| Reference | <p style=/line-height:25px/> <br>[2]. Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A. Blood Coagul Fibrinolysis. 2010 Oct;21(7):615-9. <br>[3]. Sánchez-Luceros A, Meschengieser SS, Woods AI et al. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history. Thromb Haemost. 2010 Nov;104(5):984-9. <br>[4]. Alonso DF, Ripoll GV, Garona J et al. Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr Pharm Biotechnol. 2011 Nov;12(11):1974-80. <br>[5]. Tsukamoto I. Recent patenting activities in the discovery and development of vasopressin V2 receptor agonists. Expert Opin Ther Pat. 2012 Jun;22(6):579-86. </p> |
